Coronavirus Breaking News

The coronavirus disease COVID-19 is currently reaching pandemic levels in various countries.

Nov 1, 2020 • 6:18 am CST

Researchers based in Germany developed a highly specific and sensitive approach to measuring antibodies against the new SARS-CoV-2 coronavirus for population-scale immune surveillance. The antibody positivity was defined as a dual-positive response against both the receptor-binding domain and nucleocapsid proteins of SARS-CoV-2.

In this study of 15,771 children aged 1 to 18 years living in Bavaria, Germany published on October 28, 2020, the antibody prevalence from April 2020 was 6-fold higher than 'authority-reported' cases. And showed marked variation between the (7) Bavarian regions and was not associated with age or sex.

The transmission in children with virus-positive family members was 35%, with 47% of positive children found to be asymptomatic. A positive highlight from this study was the antibody frequency in newborns was just 0.47%.

Medical Review by
Nov 1, 2020 • 5:53 am CST

Seattle-based Amazon Web Services (AWS) announced 'We are now open-sourcing a toolset for researchers and data scientists to better model and understand the progression of COVID-19 in a given community over time. This toolset is comprised of a disease progression simulator and several machine learning (ML) models to test the impact of various interventions.'

On October 30, 2020, AWS stated 'the ML models help bootstrap the system by estimating the disease progression and comparing the outcomes to historical data. Next, you can run the simulator with learned parameters to play out what-if scenarios for various interventions.'

To get started, AWS published a few sample ML simulations at the state and country levels in the covid19_simulator.ipynb notebook in https://github.com/aws-samples/covid19-simulation, which you can run on Amazon SageMaker or a local environment.

Medical Review by
Oct 31, 2020 • 7:33 pm CDT

The UK's Prime Minister Boris Johnson gave a statement at the coronavirus press conference on October 31, 2020: 'So now is the time to take action because there is no alternative... during the COVID-19 pandemic. From Thursday until the start of December 2020, you must stay at home.'

'You may only leave home for specific reasons, including for education and if you cannot work from home; For exercise and recreation outdoors, with your household or on your own with one person from another household; For medical reasons, appointments and to escape injury or harm; To shop for food and essentials; And to provide care for vulnerable people, or as a volunteer.'

'I’m afraid non-essential shops, leisure, and entertainment venues will all be closed. Pubs, bars, restaurants must close except for takeaway and delivery services.'

And, 'Single adult households can still form exclusive support bubbles with one other household, and children will still be able to move between homes if their parents are separated. If you are clinically vulnerable, or over the age of 60, you should be especially careful to follow the rules and minimize your contacts with others.' stated Prime Minister Johnson.

Medical Review by
Oct 31, 2020 • 5:51 pm CDT

Based on the evidence that non-medical face masks prevent the spread of SARS-CoV-2, various governments are mandating the wearing of masks in the community. However, fueled partly by media claims that masks can cause hypoxia and are therefore dangerous, concerns have emerged about the safety of wearing face masks.

In a new, small crossover study published by JAMA on October 30, 2020, wearing a 3-layer non-medical face mask was not associated with a decline in oxygen saturation in older participants. This means results that wearing non-medical face masks in community settings is safe.

Medical Review by
Oct 31, 2020 • 9:24 am CDT

The Russian Direct Investment Fund, União Química Farmacêutica Nacional, and the Government of the State of Parana announce on October 30, 2020, the preliminary submission of a set of documents for registration of a Russian vaccine, Sputnik V, to the Brazilian National Sanitary Inspection Agency.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund stated in a press release: "Registration will allow in the near future to start production and distribution of the vaccine in Brazil."

Medical Review by
Oct 31, 2020 • 9:08 am CDT

To survive, humans need oxygen going from our lungs to the cells in our body. Sometimes the amount of oxygen in our blood can fall below normal levels. When the levels are too low, we may need to take extra oxygen, known as oxygen therapy, says the U.S. FDA.

To clarify this health risk during the COVID-19 pandemic, the FDA issued a Consumer Update on October 30, 2020, “Pulse Oximeters and Oxygen Concentrators: What to Know About At-Home Oxygen Therapy.”

'COVID-19 is one of many health issues that may cause oxygen levels to drop. When the levels are too low, consumers may need to take extra oxygen, known as oxygen therapy. One way to get extra oxygen into the body is by using an oxygen concentrator. Oxygen concentrators are medical devices required to be sold and used only with a prescription,' says the FDA.

Medical Review by
Oct 31, 2020 • 7:44 am CDT

Kenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine candidate, which is often called AZD1222. Following immunization, will be monitored over a period of 12 months to assess their health, any vaccine side-effects, and how their bodies develop immunity in response to the vaccine.

Professor Andy Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said in a press release on October 30, 2020: ‘We’re excited to see our colleagues in Kenya today joining those around the world in helping us to evaluate the ChAdOx1 nCov-2019 Oxford coronavirus vaccine, as it is important to evaluate the vaccine in as many different populations as possible.’

Kenya joins a number of countries including the United Kingdom, South Africa, and Brazil who are running trials to evaluate the ChAdOx1 nCoV-19 vaccine, with over 20,000 volunteers now taking part in trials across these countries.

Oct 30, 2020 • 4:00 pm CDT

A literature review of 14 studies published in The Journal of Infectious Diseases on October 29, 2020, found compared to younger - middle aged adults, the susceptibility to SARS-CoVo2 virus infection for children aged under 10 years of age is estimated to be significantly lower. And, there is evidence of more limited spread in schools when some mitigation measures are implemented.

Furthermore, these researchers from Harvard University and the UK suggested 'efforts should be undertaken to diminish mixing in individuals aged 18-35 years to mitigate the spread of the epidemic in the community.

Oct 30, 2020 • 3:50 pm CDT

The U.S. CDC confirmed the overall percentage of respiratory specimens testing positive for SARS-CoV-2, the coronavirus causing COVID-19, increased from 6.6% during week #42 to 7.1% during week #43. As of October 30, 2020, the virus positivity rate increased among all age groups and in all (10) regions in the USA.

Oct 30, 2020 • 2:49 pm CDT

The US Centers for Disease Control and Prevention (CDC) issued a Framework for Conditional Sailing Order on October 30, 2020, that outlines actionable items for the cruise line industry to follow so they can resume passenger operations with an emphasis on preventing the further spread of COVID-19 on cruise ships and from cruise ships into communities, and to protect public health and safety.

Robert R. Redfield, M.D., the CDC's director stated in a press release “the cruise industry has a shared goal to protect crew, passengers, and communities and will continue to work together to ensure that all necessary public health procedures are in place before cruise ships begin sailing with passengers.”

Oct 30, 2020 • 11:30 am CDT

The U.S. CDC's Advisory Committee on Immunization Practices (ACIP) digital meeting held in Atlanta, Georgia, on October 30, 2020, reviewed the status and actions related to COVID-19 vaccine candidates. One area of concern discussed by the ACIP membership focused on the efficacy of COVID-19 vaccine candidates for the pediatric population.

The ACIP committee’s discussion included a.) when would a COVID-19 vaccine candidate be able to present enough phase 3 study data to meet the 2-month medium efficacy data requirement, and b.) should any ‘experimental’ COVID-19 vaccine candidate be considered for a population that is minimally impacted by the current COVID-19 pandemic.

The next ACIP meeting should be able to provide clarity on these and other concerns.

Oct 30, 2020 • 8:58 am CDT

Regeneron Pharmaceuticals, Inc. announced it received on October 30, 2020, a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified.

Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold pending collection and analysis of further data on patients already enrolled.

The IDMC also recommends continuing enrollment of hospitalized patients requiring either no or low-flow oxygen as the risk/benefit remains acceptable in these cohorts. Finally, the IDMC recommends the continuation of the outpatient trial without modification.

Regeneron stated it is also informing the U.S. FDA, which is currently evaluating the REGN-COV2 treatment for a potential emergency authorization in mild-to-moderate outpatients at high risk for poor outcomes.

Medical Review by
Oct 29, 2020 • 5:33 pm CDT

Twenty commonly available fabrics and materials were evaluated by researchers from the University of Cambridge and Northwestern University, for their ability to reduce air concentrations of ultrafine particles at coughing face velocities. A 3M N95 mask and hospital-grade surgical mask were tested for the sake of comparison.

Two types of vacuum bag, a disposable HEPA vacuum bag, and a washable HEPA vacuum bag, were evaluated due to the number of people attempting to use these materials as face mask filters. Eighteen fabrics were also tested as a single layer. Lastly, fabrics were layered to represent potential mask designs.

This study's results published on September 22, 2020, found 'when fabrics were layered, a higher percentage of ultrafine particles were filtered.'

The average filtration efficiency of single layer fabrics and of the layered combination was found to be 35% and 45%, respectively. Non-woven fusible interfacing, when combined with other fabrics, could add up to 11% additional filtration efficiency.

Oct 29, 2020 • 1:13 pm CDT

MIT researchers announced they have now found that people who are asymptomatic may differ from healthy individuals in the way they cough. These differences are not decipherable to the human ear. But it turns out that they can be picked up by artificial intelligence.

In a paper published in the IEEE Journal of Engineering in Medicine and Biology, the MIT team reports on an AI model that distinguishes asymptomatic people from healthy individuals through forced-cough recordings, which people voluntarily submitted through web browsers and devices such as cellphones and laptops.

“The effective implementation of this group diagnostic tool could diminish the spread of the pandemic if everyone uses it before going to a classroom, a factory, or a restaurant,” said co-author Brian Subirana, a research scientist in MIT’s Auto-ID Laboratory, in a press release issued on October 29, 2020.

Ultimately, they 'envision that audio AI models like the one they’ve developed may be incorporated into smart speakers and other listening devices so that people can conveniently get an assessment of their disease risk, perhaps on a daily basis.'

Oct 29, 2020 • 9:48 am CDT

Nasal rinses and mouthwashes, which directly impact the major sites of reception and transmission of human coronaviruses (HCoV), may provide an additional level of protection against the new SARS-CoV2 virus, reported researchers in a study published on September 17, 2020.

They found 'common over‐the‐counter nasal rinses and mouthwashes - gargles were tested for their ability to inactivate high concentrations of HCoV using contact times of 30 s, 1 min, and 2 min. Reductions in titers were measured by using the tissue culture infectious dose 50 assays.'

And, '1% baby shampoo nasal rinse solution inactivated HCoV greater than 99.9% with a 2‐min contact time. Several over‐the‐counter mouthwash/gargle products including Listerine‐like products were highly effective at inactivating infectious virus, even with a 30‐second contact time.'